Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5041-5046

  Zhou, Dong ^a   Chu, Wenhua ^a   Rothfuss, Justin ^a   Zeng, Chenbo ^a   Xu, Jinbin ^a   Jones, Lynne ^a   Welch, Michael J ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase 3; Positron emission tomography

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CYCLOHEXIMIDE; INTERLEUKIN 1BETA CONVERTING ENZYME; ISATIN DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE; TRACER; UNCLASSIFIED DRUG; WC II 89; WC II 89 F 18;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG PURITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; IN VIVO STUDY; ISOTOPE LABELING; LIVER; MALE; MICRORADIOGRAPHY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTUM YIELD; RADIOCHEMISTRY; RAT; SPLEEN; TISSUE DISTRIBUTION; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CASPASE 7; CASPASES; FLUORINE RADIOISOTOPES; ISATIN; LIVER; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RATS; RECOMBINANT PROTEINS; SPLEEN; SULFONAMIDES; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 33747355468     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.045     Document Type: Article

References (22)

1. Jacobson M.D., Weil M., and Raff M.C. Cell 88 (1997) 347
2. Reed J.C. Nat. Rev. Drug Disc. 1 (2002) 111
3. Rodriguez I., Matsuura K., Ody C., Nagata S., and Vassalli P. J. Exp. Med. 184 (1996) 2067
4. White E. Gene Dev. 10 (1996) 1
5. Ashkenazi A., and Dixit V.M. Science 281 (1998) 1305
6. Evan G., and Littlewood T. Science 281 (1998) 1317
7. Green D.R., and Reed J.C. Science 281 (1998) 1309
8. Thornberry N.A., and Lazebnik Y. Science 281 (1998) 1312
9. Dive C., and Hickman J.A. Br. J. Cancer 64 (1991) 192
10. Review see. Lahorte C.M.M., Vanderheyden J., Steinmetz N., Van De Wiele C., Dierckx R.A., and Slegers G. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 887
11. Neuss M., Crow M.T., Chesley A., and Lakatta E.G. Cardiovasc. Drugs Ther. 15 (2001) 507
12. Chu W., Zhang J., Zeng C., Rothfuss J., Tu Z., Chu Y., Reichert D.E., Welch M.J., and Mach R.H. J. Med. Chem. 48 (2005) 7637
13. 2: C, 56.66; H, 4.92; N, 4.56. Found: C, 56.74; H, 4.88; N, 4.67.
14. Yoo J., Dence C.S., Sharp T.L., Katzenellenbogen J.A., and Welch M.J. J. Med. Chem. 48 (2005) 6366
15. R = 15 min.
16. Ledda-Columbano G.M., Coni P., Faa G., Manenti G., and Columbano A. Am. J. Pathol. 140 (1992) 545
17. Faa G., Ledda-Columbano G.M., Ambu R., Congiu T., Conti P., Riva A., and Columbano A. Liver 14 (1994) 270
18. Yagle K.J., Eary J.F., Tait J.T., Grierson J.R., Link J.M., Lewellen B., Gibson D.F., and Krohn K.A. J. Nucl. Med. 46 (2005) 658
19. 18F]WC-II-89 via the tail vein. Treated rats also received 5 mg/kg cycloheximide in saline via the tail vein three hours prior to radiotracer administration in order to induce caspase-mediated liver apoptosis. At set time-points following radiopharmaceutical injection, rats were again anesthetized and euthanized. Target and non-target organs were removed, weighed, and the radioactivity was counted using a Beckman Gamma 8000 well counter. Standard dilutions of the injected dose were counted along with the samples and uptake was calculated and reported as percent injected dose per gram (%ID/g).
20. ® WestDura extended duration substrate (Pierce Biotechnology, Rockford, IL) was used for detection.
21. 18F]WC-II-89 for a one hour dynamic imaging session. MicroPET images were reconstructed with OSEM-2D data analysis software package (Siemens/CTI, Knoxville, TN).
22. Faust A., Wagner S., Keul P., Schober O., Levkau B., Schaefers M., and Kopka K. J. Labelled Compd. Radiopharm. 48 (2005) S260 (abstract)